ArticleNature medicine2023
Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants.
Article in Nature medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 81 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed, 2 syntheses or guidelines pooled it, 117 citations in OpenAlex.
- RSV-associated acute otitis media in children under five years old: a systematic review and meta-analysis.Journal of global health · 2026Pooled it
- Nirsevimab for preventing respiratory syncytial virus lower respiratory tract infections in infants: a systematic review and meta-analysis.Frontiers in public health · 2025Pooled it
- Maternal RSV Vaccination, Infant Nirsevimab, or Both: Interim Analysis of a Randomized Trial.Pediatrics · 2026Trial
- Lower Respiratory Tract Infections Following Respiratory Syncytial Virus Monoclonal Antibody Nirsevimab Immunization Versus Placebo: Analysis From a Phase 3 Randomized Clinical Trial (MELODY).Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Trial
- Replacing serum with dried blood microsampling for pharmacokinetics, viral neutralisation and immunogenicity bioanalysis supporting future paediatric development of RSM01, a candidate respiratory syncytial virus neutralising monoclonal antibody.BMC infectious diseases · 2024Trial
- Infants Receiving a Single Dose of Nirsevimab to Prevent RSV Do Not Have Evidence of Enhanced Disease in Their Second RSV Season.Journal of the Pediatric Infectious Diseases Society · 2024Trial
- Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials.Nature communications · 2023Trial
- Infant respiratory syncytial virus and childhood asthma: a nationwide registry-based, sibling-controlled, and genome-wide association study.The Lancet regional health. Europe · 2026Article
- Regional inequality in infant RSV morbidity and mortality burden in the era of expanded RSV passive immunisation: a global projection modelling study.EClinicalMedicine · 2026Article
- Diagnostic performance and interchangeability of two commercial anti-RSV-IgG and IgA ELISAs across clinically relevant populations.Microbiology spectrum · 2026Article
- Cost-Effectiveness of Immunising Interventions to Reduce Respiratory Syncytial Virus Disease Burden in Infants in Australia.PharmacoEconomics · 2026Article
- Real-world impact of nirsevimab immunisation and maternal RSV vaccination against respiratory disease on emergency department attendances and admissions: a multinational retrospective analysis.The Lancet regional health. Europe · 2026Article
- Cost-Effectiveness of Nirsevimab and Clesrovimab in Preventing Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants in the United States: A Modeling Study.Infectious diseases and therapy · 2026Article
- The influence of age-dependent susceptibility on RSV transmission dynamics and immunisation population-level impact.BMC medicine · 2026Article
- Respiratory syncytial virus mRNA vaccine-induced immunity and protection against subgroups A and B in mice.ImmunoHorizons · 2026Article
- Uncovering the post-pandemic timing of influenza, RSV, and COVID-19 driving seasonal influenza-like illness in the United States: a retrospective ecological study.Lancet regional health. Americas · 2026Article
- Two-season effectiveness of a single nirsevimab dose against RSV hospitalisation in healthy term-born infants: a population-based case-control study, Spain, October 2023 to March 2025.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2026Article
- Effectiveness of Maternal Respiratory Syncytial Virus Vaccination in Conferring Infant Immunity: Review and Future Perspectives.Vaccines · 2026Review
- Serological evidence of substantial respiratory syncytial virus infection burden among older adults residing in Swedish long-term care facilities.BMC medicine · 2026Article
- Corrected and republished from: "Clinical validation of an RSV neutralization assay and analysis of cross-sectional sera associated with 2021-2023 RSV outbreaks to investigate the immunity debt hypothesis".Microbiology spectrum · 2026Article
21 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
11 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nirsevimab is an extended half-life monoclonal antibody specific for the prefusion conformation of the respiratory syncytial virus (RSV) F protein, which has been studied in preterm and full-term infants in the phase 2b and phase 3 MELODY trials. We analyzed serum samples collected from 2,143 infants during these studies to characterize baseline levels of RSV-specific immunoglobulin G antibodies and neutralizing antibodies (NAbs), duration of RSV NAb levels following nirsevimab administration, the risk of RSV exposure during the first year of life and the infant's adaptive immune response to RSV following nirsevimab administration. Baseline RSV antibody levels varied widely; consistent with reports that maternal antibodies are transferred late in the third trimester, preterm infants had lower baseline RSV antibody levels than full-term infants. Nirsevimab recipients had RSV NAb levels >140-fold higher than baseline at day 31 and remained >50-fold higher at day 151 and >7-fold higher at day 361. Similar seroresponse rates to the postfusion form of RSV F protein in nirsevimab recipients (68-69%) compared with placebo recipients (63-70%; not statistically significant) suggest that while nirsevimab protects from RSV disease, it still allows an active immune response. In summary, nirsevimab provided sustained, high levels of NAb throughout an infant's first RSV season and prevented RSV disease while allowing the development of an immune response to RSV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.